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Abstract 
There have been more than 850,000 confirmed cases and over 48,000 deaths 
from the human coronavirus disease 2019 (COVID-19) pandemic, caused by 
novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the 
United States alone. However, there are currently no proven effective 
medications against COVID-19. Drug repurposing offers a promising way for 
the development of prevention and treatment strategies for COVID-19. This 
study reports an integrative, network-based deep learning methodology to 
identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we 
built a comprehensive knowledge graph that includes 15 million edges across 
39 types of relationships connecting drugs, diseases, genes, pathways, and 
expressions, from a large scientific corpus of 24 million PubMed publications. 
Using Amazon’s AWS computing resources, we identified 41 repurposable 
drugs (including indomethacin, toremifene and niclosamide) whose 
therapeutic association with COVID-19 were validated by transcriptomic and 
proteomic data in SARS-CoV-2 infected human cells and data from ongoing 
clinical trials. While this study, by no means recommends specific drugs, it 
demonstrates a powerful deep learning methodology to prioritize existing 
drugs for further investigation, which holds the potential of accelerating 
therapeutic development for COVID-19. 
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Introduction 
As of April 22, 2020, there have been more than 850,000 confirmed cases 
and over 48,000 deaths from Coronavirus Disease 2019 (COVID-19), the 
disease caused by the virus SARS-CoV-2, in the United States alone.1 
However, there are currently no proven effective antiviral medications against 
COVID-19.2 There is an urgent need for the development of effective 
treatment strategies for COVID-19. Traditional de novo drug discovery was 
estimated that pharmaceutical companies spent $2.6 billion in 2015 for the 
development of an FDA-approved new chemical entity drug.3 Drug 
repurposing, a drug discovery strategy from existing drugs, offers an 
promising way for the development of prevention and treatment strategies for 
COVID-19.4 
      In a randomized, controlled, open-label trial5, lopinavir and ritonavir 
combination therapy did not show clinical benefit compared to standard care 
for hospitalized adult patients with severe COVID-19, limiting the traditional 
antiviral treatment for COVID-19. SARS-CoV-2 replication and infection 
depends on the host cellular factors (including angiotensin-converting enzyme 
2 (ACE2)) for entry into cells.6 Systematic identification of virus-host protein-
protein interactions (PPIs) offers an effective way towards elucidation of the 
mechanisms of viral infection; furthermore, targeting cellular virus-host 
interactome offers a promising strategy for the development of effective drug 
repurposing for COVID-19 as demonstrated in previous studies.7-9 We 
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recently demonstrated that network-based methodologies leveraging 
relationship between drug targets and diseases can serve as a useful tool for 
efficient screening of potentially new indications for FDA-approved drugs with 
well-established pharmacokinetics/pharmacodynamics, safety and tolerability 
profiles.10-12 Yet, without foreknowledge of the complex networks connecting 
drugs, targets, SARS-CoV-2 and diseases, development of affordable 
approaches for effective treatment of COVID-19 is challenging. 
      Prior knowledge of networks from large scientific corpus of publications 
offers a deep biological perspective for capturing the relationships between 
drugs, genes and diseases (including COVID-19). Yet, extracting connections 
from a large-scale repository of structured medical information is challenging. 
In this study, we present the state-of-the-art knowledge graph-based, deep 
learning methodologies for rapid discovery of drug candidates to treat COVID-
19 from 24 million PubMed publications. Via systematic validation using 
transcriptomics and proteomics data generated from SARS-CoV-2 infected 
human cells and the ongoing clinical trial data, we successfully identified 41 
drug candidates that can be further tested in large-scale randomized control 
trials for potential treatment of COVID-19.  
 
Results 
Pipeline of CoV-KGE 

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Here we present a knowledge graph-based, deep learning methodology for 
drug repurposing in COVID-19, termed CoV-KGE (Figure 1). Our method 
uses DGL-KE, developed by our Amazon’s AWS AI Laboratory13, to efficiently 
learn embeddings of large knowledge graphs. Specifically, we construct a 
knowledge graph from 24 million PubMed publications14 and DrugBank15, 
including 15 million edges across 39 types of relationships connecting drugs, 
diseases, genes, anatomies, pharmacologic classes, gene/protein expression, 
and others (cf. Supplementary Tables 1 and 2). In this knowledge graph, we 
represent the Coronaviruses (CoVs) by assembling multiple types of known 
CoVs, including SARS-CoV-1, MERS-CoV, HCoV-229E, and HCoV-NL63 as 
described in our recent study9. 
We next utilize DGL-KE’s knowledge graph embedding model, RotatE16, 
to learn representations of the entities (e.g., drugs and targets) and 
relationships (e.g., inhibition relation between drugs and targets) in an 
informative, low-dimensional vector space. In this space, each relationship 
type (e.g., antagonists or agonists) is defined as a rotation from the source 
entity (e.g., hydroxychloroquine) to the target entity (e.g., toll-like receptor 7/9 
(TLR7/9)) (cf. Methods). 
 
High performance of CoV-KGE   
After mapping drugs, CoVs, and the treatment relationships to a complex 
vector space using RotatE, the top-100 most relevant drugs are selected as 


6 
candidate for CoVs in the treatment relation space (Supplementary Figure 
1). Using the ongoing COVID-19 trial data (https://covid19-trials.com/) as a 
validation set, CoV-KGE has the larger area under the receive operating 
characteristic curve (AUROC = 0.85, Figure 2) in identifying repurposable 
drugs for COVID-19. 
     We next employ t-SNE (t-distributed stochastic neighbor embedding 
algorithm17) to further investigate the low-dimensional node representation 
learned by CoV-KGE. Specifically, we project drugs grouped by the first-level 
of the Anatomical Therapeutic Chemical (ATC) classification systems code 
onto two-dimensional space. Figure 3A indicates that CoV-KGE is able to 
distinguish 14 types of drugs grouped by ATC codes, consistent with a high 
AUROC value of 0.85 (Figure 2). 
We further validate the top candidate drugs using enrichment analysis of 
drug-gene signatures and SARS-CoV induced transcriptomics and proteomics 
data in human cell lines (cf. Methods). Specifically, we analyzed three 
transcriptomic datasets in SARS-CoV-1 infected human cell lines and one 
proteomic dataset in SARS-CoV-2 infected human cell lines. In total, we 
obtained 41 high-confidence repurposable drugs (Supplementary Table 3)
using subject matter expertise based on a combination of factors: (i) strength 
of the CoV-KGE predicted score; (ii) availability of clinical evidence from 
ongoing COVID-19 trials; (iii) availability and strength of enrichment analyses 
from SARS-CoV-1/2 effected human cell lines. Among the 41 candidate 

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drugs, 11 drugs are or have been under clinical trials for COVID-19, including 
thalidomide, methylprednisolone, ribavirin, umifenovir, chloroquine, 
hydroxychloroquine, tetrandrine, suramin, dexamethasone, lopinavir, 
azithromycin (Figure 3A and Supplementary Table 3). We next turn to 
highlight three types of predicted drugs for COVID-19, including anti-
inflammatory agents, selective estrogen receptor modulators (SERMs), and 
antiparasitics (Figure 3A). 
 
Discovery of drug candidates for COVID-19 using CoV-KGE 
Given the well-described lung pathophysiological characteristics and immune 
responses (cytokine storms) of severe COVID-19 patients, drugs that dampen 
the immune responses may offer effective treatment approaches for COVID-
19.18, 19 As shown in Figure 3A, we computationally identified multiple anti-
inflammatory agents for COVID-19, including indomethacin and melatonin. 
Indomethacin, an approved cyclooxygenases (COXs) inhibitor, has been 
widely used for its potent anti-inflammatory and analgesic properties20. 
Indomethacin has been reported to have antiviral properties, including SARS-
CoV-120, and SARS-CoV-221. Importantly, preliminary in vivo observation 
showed that oral indomethacin (1 mg/kg body weight daily) reduced the 
recovery time of SARS-CoV-2 infected dogs.21 Melatonin plays a key role in 
the regulation of human circadian rhythm that alters the translation of 
thousands of genes, including melatonin-mediated anti-inflammatory and 
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immune-related effects for COVID-19. Melatonin has various antiviral activities 
by suppressing multiple inflammatory pathways22, 23 (including IL6, IL-1β, and 
TNFα, etc.) -- these inflammatory effects are directly relevant given the well-
described lung pathophysiological characteristics of severe COVID-19 
patients. The melatonin’s mechanism-of-action may also help explain the 
epidemiologic observation that children, who have naturally high melatonin 
levels, are relatively resistant to COVID-19 disease manifestations, while 
older individuals, who have decreasing melatonin levels with age, are a very 
high-risk population.24 In addition, exogenous melatonin administration may 
be of particular benefit to older patients given an aging-related reduction of 
endogenous melatonin levels and vulnerability of older individuals to the 
lethality of SARS-CoV-2.24  
An overexpression of estrogen receptor has played a crucial role in 
inhibiting viral replication and infection.25 Several selective estrogen receptor 
modulators (SERMs), including clomifene, bazedoxifene, and toremifene, are 
identified as promising candidate drugs for COVID-19 (Figure 3B). 
Toremifene, the first generation of nonsteroidal SERM, was reported to block 
various viral infections at low micromolar concentration, including Ebola 
virus26, 27, MRES-CoV28, SARS-CoV-129, and SARS-CoV-230 (Figure 3A). 
Toremifene prevents fusion between the viral and endosomal membrane by 
interacting with and destabilizing the virus glycoprotein, and eventually 
blocking replications of the Ebola virus.26 The underlying antiviral mechanisms 
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of SARS-CoV-1 and SARS-CoV-2 for toremifene remains unclear and are 
currently being investigated. Toremifene has been approved for the treatment 
of advanced breast cancer31 and has also been studied in men with prostate 
cancer (~1,500 subjects) with reasonable tolerability.32 Toremifene is 99% 
bound to plasma protein with good bioavailability and typically administered at 
a dosage of 60 mg orally.33 In summary, toremifene offers a promising 
candidate drug with ideal pharmacokinetics properties to be tested in COVID-
19 clinical trials directly. 
Hydroxychloroquine and chloroquine phosphate, two approved 
antimalarial drugs, though lacking strong clinical evidence, were authorized by 
the U.S. FDA for treatment of COVID-19 patients using emergency use 
authorizations.2 In this study, we identified that both hydroxychloroquine and 
chloroquine are among the predicted candidates for COVID-19 (Figure 3A). 
Between the two, hydroxychloroquine’s in vitro antiviral activity against SARS-
CoV-2 is stronger than that of chloroquine (hydroxychloroquine: 50% effective 
concentration (EC50) = 6.14 μM where chloroquine: EC50 = 23.90 μM)34. 
Hydroxychloroquine and chloroquine are known to increase the pH of 
endosomes, which inhibits membrane fusion, a required mechanism for viral 
entry (including SARS-CoV-2) into the cell19. Additionally, the potential benefit 
of hydroxychloroquine in COVID-19 patients may be explained by both 
antiviral and anti-inflammatory effects (Figure 3B). In vitro experiments 
showed that hydroxychloroquine reduced the expression of vascular cell 
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adhesion molecule 1 (VCAM1) and IL-1β and attenuates the suppression of 
endothelial nitric oxide synthase (NOS3) in human aortic endothelial cells.10 
However, even though chloroquine and hydroxychloroquine are relatively well 
tolerated, several adverse effects (including QT prolongation) limit its clinical 
use for COVID-19 patients, especially for patients with pre-existing 
cardiovascular disease or diabetes.10, 35-37 These findings suggest that 
hydroxychloroquine have both anti-inflammatory and antiviral activity for 
COVID-19 therapy but its safety and efficacy needs to be tested in large-scale 
randomized control trials. In addition, niclosamide, an FDA-approved drug for 
treatment of tapeworm infestation, was recently identified to have a stronger 
inhibitory activity on SARS-CoV-2 at sub-micromolar (IC50 = 0.28 µM).Gassen 
et al. showed that niclosamide inhibited SKP2 activity by enhancing 
autophagy and reducing MERS-CoV replication as well.38 Altogether, 
niclosamide offers another promising drug candidate for COVID-19, which is 
warranted to be investigated in randomized controlled trials further. 
     Finally, given the up-regulation of systemic inflammation—in some 
cases culminating to a cytokine storm observed in severe COVID-19 
patients40—combination therapy with an agent targeting inflammation 
(melatonin or indomethacin) and with direct antiviral effects (toremifene and 
niclosamide) has the potential of leading to successful treatments. 
 
Discussion 

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As COVID-19 patients flood hospitals worldwide, physicians are trying to 
search effective antiviral therapies to save lives. Multiple COVID-19 vaccine 
trials are under way; yet, it might not be physically possible to make enough 
vaccine for everyone in a short period of time. Furthermore, SARS-CoV-2 
replicates poorly in multiple animals, including dogs, pigs, chickens, and 
ducks, which limits preclinical animal studies39.  
     In this study, we present CoV-KGE, a powerful, integrated AI 
methodology that can be used to quickly identify drugs that can be 
repurposed for the potential treatment of COVID-19. Our approach can 
minimize the translational gap between preclinical testing results and clinical 
outcomes, which is a significant problem in the rapid development of efficient 
treatment strategies for the COVID-19 pandemic. From a translational 
perspective, if broadly applied, the network tools developed here could help 
develop effective treatment strategies for other emerging infectious diseases 
and other emerging complex diseases as well. 
 
Methods and Materials 
Constructing the knowledge graph 
In this study, we constructed a comprehensive knowledge graph (KG) from 
GNBR14 and DrugBank41. First, from GNBR, we included in the KG relations 
corresponding to drug-gene interactions, gene-gene interactions, drug-
disease associations, and gene-disease associations. Second, from 
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DrugBank, we selected the drugs whose molecular mass is greater than 230 
daltons and also exist in GNBR—resulting in 3,481 FDA-approved and 
clinically investigational drugs. For these drugs, we included in the KG 
relationships corresponding to the drug-drug interactions, and the drug-side-
effects, drug ATC codes, drug-mechanism-of-action, drug-pharmacodynamics, 
and drug-toxicity associations. Third, we included the experimentally 
discovered coronaviruses-gene relationships from our recent work in the KG.9 
Fourth, we treated the COVID-19 context by assembling six types of 
Coronaviruses (including SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-
NL63) as a comprehensive node of Coronaviruses (CoVs), and rewired the 
connections (edges) from genes and drugs. The resulting KG contains four 
types of entities (drug, gene, disease, and drug side information), 39 types of 
relationships (Supplementary Table 1), 145,179 nodes, and 15,018,067 
edges (Supplementary Table 2). 
 
The knowledge graph embedding model RotatE 
Models for computing knowledge graph embeddings learn vectors for each of 
the entities and each of the relation types so that they satisfy certain 
properties. In our work we learned these vectors using the RotatE model.42 
Given an edge in the knowledge graph represented by the triplet (head-entity, 
relation-type, and tail-entity), RotatE defines each relation type as a rotation 
from the head entity to tail entity in the complex vector space. Specifically, if 
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ℎ, # are the vectors corresponding to the head and tail entities, respectively 
and $ is the vector corresponding to the relation type, RotaE tries to minimize 
the distance %&(ℎ, #) = *|ℎ	 ∘ 	$ − #|*               (1) 
where ∘	 denotes the Hadamard (element-wise) product. 
      In order to minimize the distance between the head and the tail entities 
of the existing triplets (positive examples) and maximize the distance among 
the non-existing triples (negative examples), we use the loss function L = −log	σ4γ − %&(h, t)8 − ∑ :(ℎ;, $, #;) log <(%&(ℎ;, #;) − =)>;?@         (2) 
where	σ is sigmoid function, γ is a margin hyperparameter with γ > 0, (ℎ;, $, #;) is a negative triplet, and :(ℎ;, $, #;) is the probability of occurrence of 
the corresponding negative sample. 
 
Details of DGL-KE package 
DGL-KE43 is a high performance, easy-to-use, and scalable package for 
learning large-scale knowledge graph embeddings with a set of popular 
models including TransE, DistMult, ComplEx, and RotatE. It includes various 
optimizations that accelerate training on knowledge graphs with millions of 
nodes and billions of edges using multi-processing, multi-GPU, and 
distributed parallelism. DGL-KE is able to compute the RotatE-based 
embeddings of our knowledge graph in around 40 minutes on an EC2 
instance with 8 GPUs under Amazon’s AWS computing resources. 

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Experimental Settings  
We divide the triplets (e.g., a relationship among drug, treatment, and 
disease) into training set, validation set, and test set in a 7:1:2 manner. We 
selected the embedding dimensionality of dim=200 for nodes and relations. 
The RotatE is trained for 16000 epochs with batch size 1024 and 0.1 as the 
learning rate. We choose γ = 12 as the margin of the optimization function in 
Supplementary Note 2.  
 
Gene-Set Enrichment Analysis 
We performed the gene set enrichment analysis to further validate the 
predicted drug candidates from CoV-KGE. We first collected three differential 
gene expression data sets of human cell lines infected by HCoVs from the 
Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/). 
Specifically, two transcriptome datasets from SARS-CoV infected patient’s 
peripheral blood 44 (GSE1739) and Calu-3 cells 45 (GSE33267) were used. 
One transcriptome data set of MERS-CoV infected Calu-3 cells 46 
(GSE122876) was selected. In addition, one SARS-CoV-2 specific proteomic 
dataset was collected from a website: https://biochem2.com/index.php/22-
ibcii/pqc/130-frontpage-pqc#coronavirus. Adjusted P value less than 0.01 was 
defined as differentially expressed genes/proteins. Differential gene 
expression in cells treated with various drugs were retrieved from the 
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Connectivity Map (CMap) database47, and were used as gene profiles for the 
drugs. We calculated an enrichment score (ES) for each CoV signature 
dataset using a previously described method 48: EF = GEFHI − EFJKL>, MNO(EFHI) ≠ MNO(EFJKL>)0, QRMQ           (3) EFHI and EFJKL> are calculated separately for the up- and down-regulated 
genes from the CoV gene signature dataset. We computed SHI/JKL> and UHI/JKL> as: S = max@YZY[ \Z[ − ](Z)& ^          (4) U = max@YZY[ \](Z)& − Z_@[ ^         (5) 
where ` = 1,2,⋯ , M are the genes of HCoV signature dataset sorted in 
ascending order by their rank in the gene profiles of the drug being computed. 
The rank of gene ` is denoted by b(`), where 1 ≤ b(`) ≤ $, with $ being the 
number of genes (12,849) from the CMap database. Then, EFHI/JKL> is set 
to SHI/JKL> if SHI/JKL> > UHI/JKL>, and is set to −UHI/JKL> if UHI/JKL> >SHI/JKL>. To quantify the significance of the ES scores, permutation tests are 
repeated 100 times using randomly generated gene lists with the same 
number of up- and down-regulated genes as the CoV signature data set. 
Drugs are considered to have significantly enriched effect if ES > 0 and P < 
0.05. 
 
Performance Evaluation 

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We introduced the area under the receiver operating characteristic (ROC) 
curve (AUROC) several evaluation metrics for evaluating performance of 
drug-target interaction prediction. The area under the receiver operating 
characteristic (ROC) curve (AUROC)49 is the global prediction performance. 
The ROC curve is obtained by calculating the true positive rate (TPR) and the 
false positive rate (FPR) via varying cutoff. 
 
Supplemental Information 
Supplemental Information can be found online. 
 
Data and Code Availability. 
Source code and data can be downloaded from https://github.com/ChengF-
Lab/CoV-KGE. 
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Figure Legends 
Figure 1. A diagram illustrating workflow of a network-based, deep learning 
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methodology (termed CoV-KGE) for drug repurposing in COVID-19. 
Specifically, a comprehensive knowledge graph that contains 15 million edges 
across 39 types of relationships connecting drugs, diseases, genes, 
pathways, and expressions, and others by incorporating data from 24 million 
PubMed publications (Supplemental Table S2). Subsequently, a deep learning 
approach (RotatE in DGL-KE) was used to prioritize high-confidence 
candidate drugs for COVID-19 under Amazon supercomputing resources (cf. 
Methods section). Finally, all CoV-KGE predicted drug candidates were future 
validated by three gene expression datasets in SARS-CoV-1 infected human 
cells and one proteomic data in SARS-CoV-2 infected human cells. 
 
Figure 2. The performance of CoV-KGE in predicting of drug canidates for 
COVID-19. Drugs under the ongoing COVID-19 trial data (https://covid19-
trials.com/) were used as the validation set. AUROC: the area under the ROC 
curve. 
 
Figure 3. A diagram illustrating the landscape of CoV-KGE predicted 
repurposable drugs for COVID-19. (A) Visualization of the drug vector learned 
by knowledge graph embedding using the t-SNE (t-distributed stochastic 
neighbor embedding algorithm17). The two-dimensional (2D) representation of 
the learned vectors for 14 types of drugs grouped by the first-level of the 
Anatomical Therapeutic Chemical (ATC) classification system codes. 


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Semantically similar ATC drugs are mapped to nearby representations. We 
highlight the 11 drugs which are under clinical trials for COVID-19 and 3 
experimentaly drugs (toremifine, niclosamide and indomethasin) having 
striking in vitro antiviral activitities across Ebola virus26, 27, MRES-CoV28, 
SARS-CoV-129, and SARS-CoV-230. (B) A proposed mechanism-of-action of 
hydroxychloroquine in potential treatment of COVID-19. Hydroxychloroquine 
has both anti-inflammatory10 and antiviral activity34. Given the up-regulation of 
systemic inflammation (e.g., cytokine storms) observed in severe COVID-19 
patients40, combination therapy with antiviral agents (toremifene or 
niclosamide) and with anti-inflammatoray agents (melatonin or indomethacin) 
may offer promising treatment approach for COVID-19, which is warranted to 
be tested in the randomized controlled trials further. 
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